In the BioHarmony Drug Report Database
Lefamulin
Xenleta (lefamulin) is a small molecule pharmaceutical. Lefamulin was first approved as Xenleta on 2019-08-19. It is used to treat bacterial pneumonia in the USA. It has been approved in Europe to treat bacterial pneumonia and community-acquired infections. Xenleta’s patents are valid until 2031-05-23 (FDA).
Trade Name
|
Xenleta |
|---|---|
Common Name
|
lefamulin |
ChEMBL ID
|
CHEMBL3291398 |
Indication
|
bacterial pneumonia, community-acquired infections |
Drug Class
|
Antibacterials, pleuromulin derivatives |
Image (chem structure or protein)